AU2002236753B2 - An improved process for preparing pure ondansetron hydrochloride dihydrate - Google Patents

An improved process for preparing pure ondansetron hydrochloride dihydrate Download PDF

Info

Publication number
AU2002236753B2
AU2002236753B2 AU2002236753A AU2002236753A AU2002236753B2 AU 2002236753 B2 AU2002236753 B2 AU 2002236753B2 AU 2002236753 A AU2002236753 A AU 2002236753A AU 2002236753 A AU2002236753 A AU 2002236753A AU 2002236753 B2 AU2002236753 B2 AU 2002236753B2
Authority
AU
Australia
Prior art keywords
hydrochloride dihydrate
ondansetron
ondansetron hydrochloride
weight
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2002236753A
Other languages
English (en)
Other versions
AU2002236753A1 (en
Inventor
Eliezer Bachar
Ramy Lidor Hadas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2002236753A1 publication Critical patent/AU2002236753A1/en
Application granted granted Critical
Publication of AU2002236753B2 publication Critical patent/AU2002236753B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
AU2002236753A 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate Expired - Fee Related AU2002236753B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26105201P 2001-01-11 2001-01-11
US60/261,052 2001-01-11
PCT/US2002/000853 WO2002055492A2 (en) 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate

Publications (2)

Publication Number Publication Date
AU2002236753A1 AU2002236753A1 (en) 2003-02-06
AU2002236753B2 true AU2002236753B2 (en) 2007-06-28

Family

ID=22991757

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002236753A Expired - Fee Related AU2002236753B2 (en) 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate

Country Status (21)

Country Link
EP (1) EP1355881A4 (is)
JP (1) JP2004526692A (is)
KR (3) KR20060113792A (is)
CN (2) CN101045704A (is)
AU (1) AU2002236753B2 (is)
CA (1) CA2433720A1 (is)
CZ (1) CZ20032090A3 (is)
DE (1) DE02703115T1 (is)
ES (1) ES2219201T1 (is)
HR (1) HRP20030631A2 (is)
HU (1) HUP0400767A2 (is)
IL (1) IL156835A0 (is)
IS (1) IS6869A (is)
MX (1) MXPA03006215A (is)
NO (1) NO20033147L (is)
PL (1) PL368837A1 (is)
SK (1) SK9892003A3 (is)
TR (1) TR200401460T3 (is)
WO (1) WO2002055492A2 (is)
YU (1) YU56103A (is)
ZA (1) ZA200305338B (is)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098345B2 (en) 2002-04-29 2006-08-29 TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
FI6164U1 (fi) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronmuotoja
GB2398071B (en) * 2003-01-24 2006-06-07 Synthon Bv Process for making ondansetron and intermediate thereof
US7696356B2 (en) 2004-08-17 2010-04-13 Taro Pharmaceutical Industries Limited Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom
US7547791B2 (en) * 2004-10-26 2009-06-16 Ipca Laboratories Ltd. One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4835173A (en) * 1986-12-17 1989-05-30 Glaxo Group Limited Method of medical treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1498216A (zh) * 2000-10-30 2004-05-19 ������ҩ��ҵ���޹�˾ 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4835173A (en) * 1986-12-17 1989-05-30 Glaxo Group Limited Method of medical treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Zhongguo yiyao Gongye Zazhi, Chinese Journal of Pharmaceuticals, 1993, 24 (6): 241-242 *

Also Published As

Publication number Publication date
JP2004526692A (ja) 2004-09-02
TR200401460T3 (is) 2004-08-23
SK9892003A3 (en) 2004-05-04
CZ20032090A3 (cs) 2004-08-18
EP1355881A2 (en) 2003-10-29
MXPA03006215A (es) 2005-02-17
KR20070054749A (ko) 2007-05-29
IS6869A (is) 2003-07-08
DE02703115T1 (de) 2004-10-21
KR20060113792A (ko) 2006-11-02
CN101045704A (zh) 2007-10-03
YU56103A (sh) 2006-05-25
KR20030068583A (ko) 2003-08-21
HRP20030631A2 (en) 2005-06-30
NO20033147D0 (no) 2003-07-09
ZA200305338B (en) 2004-07-12
PL368837A1 (en) 2005-04-04
WO2002055492A2 (en) 2002-07-18
HUP0400767A2 (hu) 2004-07-28
WO2002055492A3 (en) 2003-02-13
IL156835A0 (en) 2004-02-08
CA2433720A1 (en) 2002-07-18
ES2219201T1 (es) 2004-12-01
NO20033147L (no) 2003-09-02
EP1355881A4 (en) 2004-03-31
CN1496350A (zh) 2004-05-12

Similar Documents

Publication Publication Date Title
AU2021202576B2 (en) Fenfluramine compositions and methods of preparing the same
US8501935B2 (en) Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto
JP7253624B2 (ja) ４－メトキシピロール誘導体の製造方法
CN105061414B (zh) 一锅法制备Brexpiprazole
EP1765782A1 (en) Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril
EP2948432B1 (en) Process for making ivabradine
EP3015453B1 (en) Process for the preparation of Clomiphene
AU2002236753B2 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
JP2008511684A (ja) アナストロゾール中間体についての精製方法
AU2002236753A1 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
US20100063299A1 (en) Process for Preparing Irbesartan
TWI291956B (en) Improved process
US5877351A (en) Preparation and purification process for 2- (dimethylamino) methyl!-1-(3-methoxphenyl)-cyclohexanol and its salts
US20020115707A1 (en) Process for preparing pure ondansetron hydrochloride dihydrate
EP3015454A1 (en) Stable solid form of trans-Clomiphene citrate
WO2003007872A2 (en) Process for the preparation of citalopram hydrobromide
EP2072510A1 (en) Crystalline form of azelastine
KR100342919B1 (ko) 트랜스체 염산 트라마돌의 분리 제조방법
EP3759081A1 (en) An improved process for the preparation of propiomazine maleate
CN110885315A (zh) 左西孟旦药重要中间体的制备方法
WO2002048120A1 (fr) Nouveaux cristaux de derives d'oxazepine et procede de production de ces derniers
WO2008095964A1 (en) Crystalline form of moxifloxacin base

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee